Published :
Tables : 63
Figures : 53
Category : Healthcare
No. of Pages : 236
Report Code : HC-U3325
PARP Inhibitors Market is poised to value USD 10417.90 million by 2028 end at a CAGR of 11.2% during the forecast period 2022 to 2028. Increasing prevalence of cancer, rising acceptance of PARP inhibitors drugs, increased geriatric population and scientific advancements in the healthcare sector across the world are some of the kay factors contributing to the growth of the market. Moreover, the key market players are introducing novel techniques for developing advanced cancer treatments which shall propel the PARP inhibitors market growth. On the other hand, strict governmental regulations and frequent product recalls are predicted to impede the market growth substantially in the upcoming years. For many years, cancer has been the leading cause of death across the world. As per the WHO, cancer is the reason for over 8 million deaths each year, with over 65% new cancer cases are anticipated to be registered over the next two decades. Rising population afflicted with cancer shall prove to be a key factor in the augmentation of the market. As per the data provided by the CDC, 2014, the number of cancer patients reached over 20 million in the United States and it is estimated that this number shall reach over 25 million by 2024 end. Additionally, the rising geriatric population getting diagnosed with cancer shall propel the growth of the market. As per the Administration for Community Living, the number of people over the age of 65 in the United States were over 46 million in 2014. Market Segmentation: By Drug Type • Lynaprza • Niraparib • Rucaparib • Talazoparib • Veliparib • Others By Indication • Ovarian Cancer • Breast Cancer • Prostate Cancer • Pancreatic Cancer • Lung Cancer • Others By Distribution channel • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The market is classified into drug type, indication, distribution channel and region. The drug type segment is diversified into lynaprza, niraparib, rucaparib, talazoparib, veliparib and others. The indication segment is fragmented into ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, lung cancer and others. The distribution channel segment is bifurcated into hospital pharmacies, retail pharmacies, online pharmacies and others. Regional Analysis: The North America region is expected to lead the market during the forecast period owing to the rising geriatric population, increased prevalence of cancer owing to unhealthy lifestyle and dietary choices and a strong presence of key market players in the region. Competitive Landscape: Some of the major market players associated are AstraZeneca, Tesaro, AbbVie Inc., Medivation, Clovis Oncology. AstraZeneca is primarily engaged in manufacturing, discovery, commercialization, distribution of biopharma products. It provides different services in therapeutics for metabolic and cardiovascular diseases, respiratory, oncological, autoimmunity and inflammation. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global PARP inhibitors market by drug type, by indication, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Increasing prevalence of cancer, rising acceptance of PARP inhibitors drugs, increased geriatric population and scientific advancements in the healthcare sector across the world are some of the kay factors contributing to the growth of the market. Moreover, the key market players are introducing novel techniques for developing advanced cancer treatments which shall propel the PARP inhibitors market growth. On the other hand, strict governmental regulations and frequent product recalls are predicted to impede the market growth substantially in the upcoming years. For many years, cancer has been the leading cause of death across the world. As per the WHO, cancer is the reason for over 8 million deaths each year, with over 65% new cancer cases are anticipated to be registered over the next two decades. Rising population afflicted with cancer shall prove to be a key factor in the augmentation of the market. As per the data provided by the CDC, 2014, the number of cancer patients reached over 20 million in the United States and it is estimated that this number shall reach over 25 million by 2024 end. Additionally, the rising geriatric population getting diagnosed with cancer shall propel the growth of the market. As per the Administration for Community Living, the number of people over the age of 65 in the United States were over 46 million in 2014.
Market Segmentation:
By Drug Type • Lynaprza • Niraparib • Rucaparib • Talazoparib • Veliparib • Others By Indication • Ovarian Cancer • Breast Cancer • Prostate Cancer • Pancreatic Cancer • Lung Cancer • Others By Distribution channel • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The market is classified into drug type, indication, distribution channel and region. The drug type segment is diversified into lynaprza, niraparib, rucaparib, talazoparib, veliparib and others. The indication segment is fragmented into ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, lung cancer and others. The distribution channel segment is bifurcated into hospital pharmacies, retail pharmacies, online pharmacies and others.
Regional Analysis:
The North America region is expected to lead the market during the forecast period owing to the rising geriatric population, increased prevalence of cancer owing to unhealthy lifestyle and dietary choices and a strong presence of key market players in the region.
Competitive Landscape:
Some of the major market players associated are AstraZeneca, Tesaro, AbbVie Inc., Medivation, Clovis Oncology. AstraZeneca is primarily engaged in manufacturing, discovery, commercialization, distribution of biopharma products. It provides different services in therapeutics for metabolic and cardiovascular diseases, respiratory, oncological, autoimmunity and inflammation.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global PARP inhibitors market by drug type, by indication, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. PARP Inhibitors Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of PARP Inhibitors Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. PARP Inhibitors Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. PARP Inhibitors Market, By Drug Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Lynaprza 7.2. Niraparib 7.3. Rucaparib 7.4. Talazoparib 7.5. Veliparib 7.6. Others 8. PARP Inhibitors Market, By Indication Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Ovarian Cancer 8.2. Breast Cancer 8.3. Prostate Cancer 8.4. Pancreatic Cancer 8.5. Lung Cancer 8.6. Others 9. PARP Inhibitors Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Hospital Pharmacies 9.2. Retail Pharmacies 9.3. Online Pharmacies 9.4. Others 10. North America PARP Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America PARP Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe PARP Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific PARP Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. AstraZeneca 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Tesaro 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. AbbVie Inc. 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Medivation 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Clovis Oncology 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations 18. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. PARP Inhibitors Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of PARP Inhibitors Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. PARP Inhibitors Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. PARP Inhibitors Market, By Drug Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Lynaprza 7.2. Niraparib 7.3. Rucaparib 7.4. Talazoparib 7.5. Veliparib 7.6. Others
8. PARP Inhibitors Market, By Indication Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Ovarian Cancer 8.2. Breast Cancer 8.3. Prostate Cancer 8.4. Pancreatic Cancer 8.5. Lung Cancer 8.6. Others
9. PARP Inhibitors Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Hospital Pharmacies 9.2. Retail Pharmacies 9.3. Online Pharmacies 9.4. Others
10. North America PARP Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028
11. Latin America PARP Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028
12. Europe PARP Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028
13. Asia Pacific PARP Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028
15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. AstraZeneca 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Tesaro 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. AbbVie Inc. 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Medivation 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Clovis Oncology 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview
17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics